INTERIM REPORT JANUARY – SEPTEMBER 2026

In Q3 2026, net sales fell 5% organically and 2% reported to SEK 9,012m from SEK 9,204m, including a positive 3% impact from exchange-rate changes. Operating income swung to a loss of SEK 334m from income of SEK 141m, with the operating margin declining to -3.7% from 1.5%. Excluding SEK 88m of items affecting comparability, primarily tied to cost-saving initiatives, operating income was still negative at SEK 246m versus SEK 140m a year earlier.

Analysis

The key signal is not the reported sales decline but that the business remains loss-making even after excluding the stated comparability charge. That weakens the case that restructuring costs alone explain the margin collapse: either demand/mix, pricing, operating leverage, or execution is still pressuring the underlying result. Currency support also makes the reported top line look less weak than the organic trend. Cost actions could improve earnings over the next 1–3 quarters, but only if savings exceed implementation costs without damaging sales or service levels.

Near term, expect investors to focus on the next update for evidence of sequential organic stabilization and a credible bridge from cost actions to positive underlying operating profit. Over 6–18 months, persistent organic contraction raises the risk of further estimate cuts and multiple compression; a recovery would require margin improvement, not just FX or restructuring adjustments. The contrarian point is that the restructuring charge may be temporary, but treating it as the whole problem is premature given the underlying loss. Company identity is not supplied, so ticker-specific peers, valuation, and trade sizing cannot be responsibly assessed.

Key Decisions for Investors

• Do not initiate a ticker-specific position until the issuer and segment mix are verified; the supplied data has no company identity, and the SEK figures alone are insufficient to map it reliably.
• Place the issuer on a short-term watchlist: seek the next quarterly evidence of organic sales stabilization and a bridge showing recurring savings translating into positive operating income excluding comparability items.
• If the underlying loss persists or guidance is reduced, consider an underweight/short only after checking valuation, liquidity, and borrow; the thesis is falsified by sustained organic growth and improving underlying margins across subsequent quarters.
• Treat any apparent near-term improvement cautiously if it is driven mainly by exchange rates or one-off cost adjustments rather than volume, pricing, and recurring cost reductions.